Join Bjoern Bornkamp, Statistical Methodologist at Novartis and Jose Pinheiro, Senior Director, Johnson & Johnson in the next webinar in the series.

Finding the right dose in Phase 2 gives a potential new therapy its best chance to demonstrate efficacy during Phase 3. A well-executed dose-ranging trial therefore has the potential to alter the course of the entire clinical development program. This webinar will demonstrate how adaptive and Bayesian techniques can be implemented for optimal dose-finding.

Complete the form to register today!